102 related articles for article (PubMed ID: 18224683)
1. Antitumor effector functions of T cells are dependent on in vivo priming and restricted T-cell receptor expression.
Lüking C; Kronenberger K; Frankenberger B; Nössner E; Röcken M; Mocikat R
Int J Cancer; 2008 May; 122(10):2280-5. PubMed ID: 18224683
[TBL] [Abstract][Full Text] [Related]
2. Divergent roles for CD4+ T cells in the priming and effector/memory phases of adoptive immunotherapy.
Hu HM; Winter H; Urba WJ; Fox BA
J Immunol; 2000 Oct; 165(8):4246-53. PubMed ID: 11035058
[TBL] [Abstract][Full Text] [Related]
3. Synergistic enhancement of antitumor immunity with adoptively transferred tumor-specific CD4+ and CD8+ T cells and intratumoral lymphotactin transgene expression.
Huang H; Li F; Gordon JR; Xiang J
Cancer Res; 2002 Apr; 62(7):2043-51. PubMed ID: 11929823
[TBL] [Abstract][Full Text] [Related]
4. The immunologic function of 1B2+ double negative (CD4-CD8-) T cells in the 2C transgenic mouse.
Margenthaler JA; Flye MW
J Surg Res; 2005 Jun; 126(2):160-6. PubMed ID: 15919414
[TBL] [Abstract][Full Text] [Related]
5. Persistence, immune specificity, and functional ability of murine mutant ras epitope-specific CD4(+) and CD8(+) T lymphocytes following in vivo adoptive transfer.
Bristol JA; Schlom J; Abrams SI
Cell Immunol; 1999 May; 194(1):78-89. PubMed ID: 10357883
[TBL] [Abstract][Full Text] [Related]
6. CD8 T cell priming in the presence of IFN-α renders CTLs with improved responsiveness to homeostatic cytokines and recall antigens: important traits for adoptive T cell therapy.
Hervas-Stubbs S; Mancheño U; Riezu-Boj JI; Larraga A; Ochoa MC; Alignani D; Alfaro C; Morales-Kastresana A; Gonzalez I; Larrea E; Pircher H; Le Bon A; Lopez-Picazo JM; Martín-Algarra S; Prieto J; Melero I
J Immunol; 2012 Oct; 189(7):3299-310. PubMed ID: 22925929
[TBL] [Abstract][Full Text] [Related]
7. NKT and CD8 lymphocytes mediate suppression of hepatocellular carcinoma growth via tumor antigen-pulsed dendritic cells.
Shibolet O; Alper R; Zlotogarov L; Thalenfeld B; Engelhardt D; Rabbani E; Ilan Y
Int J Cancer; 2003 Aug; 106(2):236-43. PubMed ID: 12800200
[TBL] [Abstract][Full Text] [Related]
8. IL-4-transduced tumor cell vaccine induces immunoregulatory type 2 CD8 T lymphocytes that cure lung metastases upon adoptive transfer.
Rodolfo M; Zilocchi C; Accornero P; Cappetti B; Arioli I; Colombo MP
J Immunol; 1999 Aug; 163(4):1923-8. PubMed ID: 10438927
[TBL] [Abstract][Full Text] [Related]
9. Suppression of hepatocellular carcinoma by transplantation of ex-vivo immune-modulated NKT lymphocytes.
Margalit M; Shibolet O; Klein A; Elinav E; Alper R; Thalenfeld B; Engelhardt D; Rabbani E; Ilan Y
Int J Cancer; 2005 Jun; 115(3):443-9. PubMed ID: 15688366
[TBL] [Abstract][Full Text] [Related]
10. Flow-microfluorometric monitoring of oligoclonal CD8+ T cell responses to an immunodominant Moloney leukemia virus-encoded epitope in vivo.
Brawand P; Biasi G; Horvath C; Cerottini JC; MacDonald HR
J Immunol; 1998 Feb; 160(4):1659-65. PubMed ID: 9469422
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive phenotypic analysis of the gut intra-epithelial lymphocyte compartment: perturbations induced by acute reovirus 1/L infection of the gastrointestinal tract.
Bharhani MS; Grewal JS; Peppler R; Enockson C; London L; London SD
Int Immunol; 2007 Apr; 19(4):567-79. PubMed ID: 17369189
[TBL] [Abstract][Full Text] [Related]
12. Clinical grade generation of hexon-specific T cells for adoptive T-cell transfer as a treatment of adenovirus infection after allogeneic stem cell transplantation.
Feuchtinger T; Richard C; Joachim S; Scheible MH; Schumm M; Hamprecht K; Martin D; Jahn G; Handgretinger R; Lang P
J Immunother; 2008; 31(2):199-206. PubMed ID: 18481389
[TBL] [Abstract][Full Text] [Related]
13. Augmentation of virus-specific immunity after hematopoietic stem cell transplantation by adoptive T-cell therapy.
Peggs KS; Mackinnon S
Hum Immunol; 2004 May; 65(5):550-7. PubMed ID: 15172456
[TBL] [Abstract][Full Text] [Related]
14. Functional CD4(+) and CD8(+) T-cell responses induced by autologous mitomycin C treated Epstein-Barr virus transformed lymphoblastoid cell lines.
Meij P; Bloemena E; Palmen N; Brink A; Vervoort MB; Meijer CJ; Middeldorp JM
Cell Immunol; 2001 Feb; 208(1):25-33. PubMed ID: 11277616
[TBL] [Abstract][Full Text] [Related]
15. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
[TBL] [Abstract][Full Text] [Related]
16. Human effector T cells derived from central memory cells rather than CD8(+)T cells modified by tumor-specific TCR gene transfer possess superior traits for adoptive immunotherapy.
Wu F; Zhang W; Shao H; Bo H; Shen H; Li J; Liu Y; Wang T; Ma W; Huang S
Cancer Lett; 2013 Oct; 339(2):195-207. PubMed ID: 23791878
[TBL] [Abstract][Full Text] [Related]
17. CD4-CD8- T cells control intracellular bacterial infections both in vitro and in vivo.
Cowley SC; Hamilton E; Frelinger JA; Su J; Forman J; Elkins KL
J Exp Med; 2005 Jul; 202(2):309-19. PubMed ID: 16027239
[TBL] [Abstract][Full Text] [Related]
18. siRNA silencing of PD-1 ligands on dendritic cell vaccines boosts the expansion of minor histocompatibility antigen-specific CD8(+) T cells in NOD/SCID/IL2Rg(null) mice.
van der Waart AB; Fredrix H; van der Voort R; Schaap N; Hobo W; Dolstra H
Cancer Immunol Immunother; 2015 May; 64(5):645-54. PubMed ID: 25724840
[TBL] [Abstract][Full Text] [Related]
19.
Hu X; Majchrzak K; Liu X; Wyatt MM; Spooner CJ; Moisan J; Zou W; Carter LL; Paulos CM
Cancer Res; 2018 Jul; 78(14):3888-3898. PubMed ID: 29769201
[TBL] [Abstract][Full Text] [Related]
20. Bryostatin 1/ionomycin (B/I) ex vivo stimulation preferentially activates L-selectinlow tumor-sensitized lymphocytes.
Chin CS; Miller CH; Graham L; Parviz M; Zacur S; Patel B; Duong A; Bear HD
Int Immunol; 2004 Sep; 16(9):1283-94. PubMed ID: 15262898
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
